TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02880163: REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Sponsor: Arsenal Medical, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,120,800

Rescue Site Savings

+$2,058,400

Unlock Full NCT02880163 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02880163 Rescue Dossier →